Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$6.99 -1.7%	$6.21	$4.02 ▼ $15.10	$379.40M	2.09	1.73 million shs	917,382 shs
IRWD Ironwood Pharmaceuticals	$0.74 +0.0%	$0.70	$0.53 ▼ $7.11	$123.95M	0.3	2.57 million shs	1.03 million shs
VSTM Verastem	$4.76 -1.9%	$6.36	$2.10 ▼ $9.10	$263.76M	0.71	1.27 million shs	1.68 million shs
XOMA XOMA Royalty	$26.43 +1.2%	$25.28	$18.35 ▼ $35.00	$322.63M	0.93	35,139 shs	25,289 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	0.00%	+10.17%	+15.25%	+54.30%	-7.29%
IRWD Ironwood Pharmaceuticals	0.00%	+1.25%	+29.60%	-44.78%	-87.89%
VSTM Verastem	0.00%	+14.70%	-22.98%	-7.75%	+61.90%
XOMA XOMA Royalty	0.00%	-3.84%	+5.74%	+35.98%	+2.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent Biosolutions	4.3204 of 5 stars	3.5	1.0	4.6	2.1	2.5	1.3
IRWD Ironwood Pharmaceuticals	4.5839 of 5 stars	4.1	5.0	3.4	0.0	0.8	1.9
VSTM Verastem	2.6413 of 5 stars	3.5	3.0	0.0	1.0	2.5	0.6
XOMA XOMA Royalty	4.3183 of 5 stars	3.5	4.0	3.0	1.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	3.00	Buy	$14.33	105.05% Upside
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	546.40% Upside
VSTM Verastem	3.00	Buy	$13.38	180.99% Upside
XOMA XOMA Royalty	3.00	Buy	$69.50	162.92% Upside

Current Analyst Ratings Breakdown

Latest IRWD, EBS, VSTM, and XOMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$16.00 ➝ $12.00
5/28/2025	XOMA XOMA Royalty	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
4/17/2025	XOMA XOMA Royalty	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
4/16/2025	IRWD Ironwood Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/15/2025	IRWD Ironwood Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00 ➝ $1.00
4/15/2025	IRWD Ironwood Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $0.70
4/14/2025	IRWD Ironwood Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform ➝ Market Perform	$3.00 ➝ $1.00
4/14/2025	IRWD Ironwood Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$1.04B	0.36	$1.92 per share	3.64	$8.91 per share	0.78
IRWD Ironwood Pharmaceuticals	$317.68M	0.38	$0.05 per share	15.49	($1.88) per share	-0.39
VSTM Verastem	$10K	26,156.20	N/A	N/A	($0.65) per share	-7.32
XOMA XOMA Royalty	$28.49M	11.11	N/A	N/A	$6.95 per share	3.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.38	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	$880K	-$0.20	N/A	2.96	N/A	-9.89%	-1.87%	-3.93%	8/6/2025 (Estimated)
VSTM Verastem	-$130.64M	-$3.20	N/A	N/A	N/A	N/A	-2,003.62%	-127.97%	8/6/2025 (Estimated)
XOMA XOMA Royalty	-$13.82M	-$1.15	N/A	N/A	N/A	-13.04%	-12.43%	-4.85%	8/12/2025 (Estimated)

Latest IRWD, EBS, VSTM, and XOMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/13/2025	Q1 2025	XOMA XOMA Royalty	-$0.26	$0.06	+$0.32	$0.06	$6.75 million	$15.91 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A
XOMA XOMA Royalty	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.20	6.32	3.51
IRWD Ironwood Pharmaceuticals	N/A	3.34	3.34
VSTM Verastem	N/A	3.50	3.50
XOMA XOMA Royalty	1.18	5.54	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
IRWD Ironwood Pharmaceuticals	N/A
VSTM Verastem	88.37%
XOMA XOMA Royalty	95.92%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	1.20%
IRWD Ironwood Pharmaceuticals	12.70%
VSTM Verastem	2.10%
XOMA XOMA Royalty	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	53.63 million	Optionable
IRWD Ironwood Pharmaceuticals	220	161.82 million	141.27 million	Optionable
VSTM Verastem	50	54.95 million	53.80 million	Optionable
XOMA XOMA Royalty	10	11.97 million	10.88 million	Optionable

IRWD, EBS, VSTM, and XOMA Headlines

Recent News About These Companies

Acuitas Investments LLC Trims Stake in XOMA Royalty Corporation (NASDAQ:XOMA)

July 2, 2025 | marketbeat.com

Top biotech deals in June 2025

July 2, 2025 | labiotech.euL

XOMA Royalty (NASDAQ:XOMA) Downgraded to "Hold" Rating by Wall Street Zen

June 29, 2025 | americanbankingnews.com

XOMA Royalty (NASDAQ:XOMA) Downgraded by Wall Street Zen to Hold

June 28, 2025 | marketbeat.com

XOMA Royalty to Buy Turnstone Biologics

June 27, 2025 | marketwatch.com

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...

June 27, 2025 | gurufocus.com

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...

June 27, 2025 | gurufocus.com

XOMA Royalty Corporation to Acquire Turnstone Biologics Corp. in Cash and CVR Merger Deal

June 27, 2025 | quiverquant.comQ

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

June 27, 2025 | globenewswire.com

XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?

June 24, 2025 | zacks.com

XOMA Royalty (NASDAQ:XOMA) Stock Crosses Above 200 Day Moving Average - Should You Sell?

June 24, 2025 | marketbeat.com

XOMA Preferred Shares Series A declares $0.539 dividend

June 18, 2025 | seekingalpha.com

XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend

June 18, 2025 | seekingalpha.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

June 18, 2025 | investing.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

June 18, 2025 | globenewswire.com

XOMA (NASDAQ:XOMA) Rating Increased to Buy at Wall Street Zen

June 14, 2025 | marketbeat.com

Positive Outlook for Xoma: Strategic Positioning and Pricing Dynamics Drive Buy Rating

May 29, 2025 | tipranks.com

XOMA boosts stake in anti-CD38 antibody with $30 million deal

May 28, 2025 | thepharmaletter.comT

XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

May 28, 2025 | benzinga.com

XOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy Rating

May 28, 2025 | tipranks.com

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD, EBS, VSTM, and XOMA Company Descriptions

Emergent Biosolutions NYSE:EBS

$6.99 -0.12 (-1.69%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$6.98 0.00 (-0.07%)

As of 07/3/2025 04:59 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.74 +0.00 (+0.04%)

As of 07/3/2025 03:46 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Verastem NASDAQ:VSTM

$4.76 -0.09 (-1.86%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$4.76 0.00 (0.00%)

As of 07/3/2025 04:45 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

XOMA Royalty NASDAQ:XOMA

$26.43 +0.32 (+1.24%)

As of 07/3/2025 01:32 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time